MX2014010364A - Composicion farmaceutica que contiene un derivado de dihidroquinazolina antiviralmente activo. - Google Patents

Composicion farmaceutica que contiene un derivado de dihidroquinazolina antiviralmente activo.

Info

Publication number
MX2014010364A
MX2014010364A MX2014010364A MX2014010364A MX2014010364A MX 2014010364 A MX2014010364 A MX 2014010364A MX 2014010364 A MX2014010364 A MX 2014010364A MX 2014010364 A MX2014010364 A MX 2014010364A MX 2014010364 A MX2014010364 A MX 2014010364A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
preparation containing
antivirally active
dihydroquinazoline derivative
dihydroquinazoline
Prior art date
Application number
MX2014010364A
Other languages
English (en)
Other versions
MX369666B (es
Inventor
Kerstin Paulus
Wilfried Schwab
Dominique Grunder
Peter Van Hoogevest
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47757622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014010364(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of MX2014010364A publication Critical patent/MX2014010364A/es
Publication of MX369666B publication Critical patent/MX369666B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas, particularmente para administración intravenosa, que contiene un ácido {8-fluoro-2-[4-(3-metoxifenil)piperazina-1-il]-3-[2-metoxi-5 -(trifluoro-metil)fenil]-3,4-dihidroquinazolina-4-il}acético en combinación con al menos uno de los excipientes de ciclodextrina, lisina y arginina; el método para su producción; y su uso en métodos de tratamiento de y/o como un profiláctico para enfermedades, particularmente en el uso como un antiviral, preferentemente contra citomegalovirus.
MX2014010364A 2012-02-29 2013-02-28 Composicion farmaceutica que contiene un derivado de dihidroquinazolina antiviralmente activo. MX369666B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012101680A DE102012101680A1 (de) 2012-02-29 2012-02-29 Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
PCT/EP2013/054114 WO2013127970A1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat

Publications (2)

Publication Number Publication Date
MX2014010364A true MX2014010364A (es) 2014-12-05
MX369666B MX369666B (es) 2019-11-14

Family

ID=47757622

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010364A MX369666B (es) 2012-02-29 2013-02-28 Composicion farmaceutica que contiene un derivado de dihidroquinazolina antiviralmente activo.

Country Status (37)

Country Link
US (1) US10603384B2 (es)
EP (3) EP4328218A3 (es)
JP (1) JP6387486B2 (es)
KR (1) KR102149561B1 (es)
CN (2) CN104144678A (es)
AU (1) AU2013224947B2 (es)
BR (1) BR112014020946B1 (es)
CA (1) CA2865203C (es)
CL (1) CL2014002306A1 (es)
CO (1) CO7061076A2 (es)
CY (1) CY1121910T1 (es)
DE (1) DE102012101680A1 (es)
DK (2) DK3556350T3 (es)
EA (1) EA026584B1 (es)
ES (2) ES2741698T3 (es)
FI (1) FI3556350T3 (es)
HK (1) HK1205462A1 (es)
HR (2) HRP20240197T1 (es)
HU (1) HUE045949T2 (es)
IL (1) IL234363B (es)
IN (1) IN2014MN01892A (es)
LT (2) LT2819648T (es)
MA (1) MA35941B1 (es)
ME (1) ME03448B (es)
MX (1) MX369666B (es)
MY (1) MY172310A (es)
NZ (1) NZ628444A (es)
PH (1) PH12014501937A1 (es)
PL (2) PL2819648T3 (es)
PT (2) PT3556350T (es)
RS (2) RS65137B1 (es)
SG (1) SG11201405294XA (es)
SI (2) SI3556350T1 (es)
TN (1) TN2014000345A1 (es)
UA (1) UA111415C2 (es)
WO (1) WO2013127970A1 (es)
ZA (1) ZA201405949B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
LT3010891T (lt) * 2013-06-19 2019-08-26 Aicuris Anti-Infective Cures Gmbh Amorfinis letermoviras ir jo kietos farmacinės kompozicijos, skirtos peroraliniam įvedimui
SG11201810836PA (en) 2016-06-03 2018-12-28 Atreya Innovations Private Ltd A device for the detection and reliable capturing of the pulse characteristics
SG11201908181XA (en) 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
UY39095A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2- [(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
CN114539085B (zh) * 2020-11-26 2023-10-20 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
CN115403528A (zh) * 2021-05-27 2022-11-29 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN113880776B (zh) * 2021-11-16 2023-06-16 山东诚创蓝海医药科技有限公司 一种莱特莫韦中间体的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN115677539B (zh) * 2022-11-01 2023-10-24 南京工业大学 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1242699A (en) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
CA1284994C (en) * 1985-08-05 1991-06-18 Murray Arthur Kaplan Cephalosporin salts and injectable compositions
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
SK287238B6 (sk) * 1999-03-17 2010-04-07 Astrazeneca Ab Amidové deriváty, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
US7939539B2 (en) * 2003-11-25 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Quinazolinone compounds as anticancer agents
EP1846410B1 (en) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
US8743287B2 (en) * 2009-07-24 2014-06-03 Broadcom Corporation Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction

Also Published As

Publication number Publication date
WO2013127970A1 (de) 2013-09-06
AU2013224947A1 (en) 2014-09-18
EA201400963A1 (ru) 2015-02-27
EP3556350A1 (de) 2019-10-23
EP4328218A3 (de) 2024-04-10
HRP20240197T1 (hr) 2024-04-26
CL2014002306A1 (es) 2014-11-28
HRP20191369T1 (hr) 2019-11-01
EP4328218A2 (de) 2024-02-28
ZA201405949B (en) 2021-07-28
CA2865203C (en) 2019-11-05
ME03448B (me) 2020-01-20
US20150133461A1 (en) 2015-05-14
CY1121910T1 (el) 2020-10-14
PT3556350T (pt) 2024-02-15
LT3556350T (lt) 2024-02-26
PL3556350T3 (pl) 2024-05-06
PH12014501937A1 (en) 2014-11-24
JP2015508801A (ja) 2015-03-23
HUE045949T2 (hu) 2020-01-28
KR20140130683A (ko) 2014-11-11
SG11201405294XA (en) 2014-11-27
EP2819648A1 (de) 2015-01-07
UA111415C2 (uk) 2016-04-25
HK1205462A1 (en) 2015-12-18
BR112014020946B1 (pt) 2022-04-05
DK3556350T3 (da) 2024-02-12
IN2014MN01892A (es) 2015-07-10
RS65137B1 (sr) 2024-02-29
SI3556350T1 (sl) 2024-03-29
CO7061076A2 (es) 2014-09-19
IL234363B (en) 2020-04-30
CN104144678A (zh) 2014-11-12
FI3556350T3 (fi) 2024-02-14
LT2819648T (lt) 2019-09-10
DK2819648T3 (da) 2019-08-26
ES2741698T3 (es) 2020-02-12
RS59157B1 (sr) 2019-10-31
EP3556350B1 (de) 2024-01-10
AU2013224947B2 (en) 2017-06-29
TN2014000345A1 (en) 2015-12-21
CN110433166A (zh) 2019-11-12
MY172310A (en) 2019-11-21
NZ628444A (en) 2016-07-29
DE102012101680A1 (de) 2013-08-29
PL2819648T3 (pl) 2019-10-31
PT2819648T (pt) 2019-09-05
EP2819648B1 (de) 2019-05-29
JP6387486B2 (ja) 2018-09-12
BR112014020946A2 (es) 2017-06-20
CA2865203A1 (en) 2013-09-06
ES2972133T3 (es) 2024-06-11
KR102149561B1 (ko) 2020-08-31
SI2819648T1 (sl) 2019-10-30
MX369666B (es) 2019-11-14
MA35941B1 (fr) 2014-12-01
EA026584B1 (ru) 2017-04-28
US10603384B2 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
TN2014000345A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
IN2014DN09434A (es)
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
WO2014076569A3 (en) Controlled release topical testosterone formulations and methods
EA201500448A1 (ru) Гуанидиновое соединение
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2013142182A3 (en) Combination therapy of a mek inhibitor and igf1r inhibitor
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp
GEP20156332B (en) Pyrazoles as crth2 antagonists
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
WO2012123924A3 (en) Antimicrobial composition including at least one or more aggregation(s) silver particles
TR201203086A2 (tr) Sefiksim ve klavulanik asit içeren farmasötik dozaj formu.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: AICURIS ANTI-INFECTIVE CURES GMBH

FG Grant or registration